Skip to content
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us

Day: November 4, 2022

AFR Higher Education Award Research Commercialisation

Australia Financial Review Logo

ImmVirX nominated for AFR Higher Education Award under the Research Commercialisation category‍ You can read the full story here.

Join Our Mailing List

Our mission is to develop receptor-targeted oncolytic RNA immunotherapies that improve outcomes for patients with cancers that are difficult to treat

About Us
Our Technology
Immvirx logo
A clinical-stage company developing receptor-targeted oncolytic RNA immunotherapies for cancers with high unmet need.
Twitter Linkedin
Company
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us

© 2026 ImmVirX Pty Ltd • Website developed by Noise